When Falutz and colleagues enrolled 412 subjects in the 2007 NEJM tesamorelin trial, the administration protocol was not an afterthought — it was a controlled variable. The 2 mg/day subcutaneous dose was administered to the periumbilical abdomen, with site rotation documented per visit. That methodological precision is a large part of why the trial achieved the 15-18% visceral adipose tissue (VAT) reduction it reported. Replicate the molecule without replicating the protocol and you are running a different experiment.
This matters for every researcher in the UAE who wants to buy tesamorelin UAE and run a clean protocol. REVIVE LAB UAE supplies HPLC-verified, lot-COA, cold-chain dispatched tesamorelin across all 7 emirates — but the vial quality only converts to reliable outcomes when the site-rotation grid is taken as seriously as the peptide itself.
Tesamorelin is a 44-amino-acid GHRH analog with a trans-3-hexenoyl N-terminal modification — the structural change that resists DPP-IV cleavage and extends its pulsatile GH-stimulating action. Subcutaneous (SC) injection deposits the peptide into the loose connective tissue below the dermis, where it diffuses into local capillaries. The abdominal wall is the preferred depot for three evidence-backed reasons:
The problem with the abdomen is also its advantage: it is a finite, well-vascularised surface. Repeated injection into the same site within a 72-hour window induces a local inflammatory micro-response. Over 2-4 weeks of daily injections without rotation, this progresses to subcutaneous lipohypertrophy — a firm, desensitised nodule that slows absorption, distorts bioavailability, and can reduce IGF-1 response by 20-30% relative to a naive site. The Falutz 2007 and Stanley 2014 research teams pre-empted this by mandating rotation. Investigators replicating those protocols should do the same.
The standard research-context abdominal rotation grid divides the periumbilical region into 8 discrete zones arranged in two rings — left and right — around the navel. The key anatomical boundaries are:
Rotating clockwise through all 8 zones before revisiting any single site gives a minimum 7-day rest per zone at once-daily dosing (8 sites ÷ 1 injection/day = 8-day cycle). For 2 mg/day protocols referencing the Falutz 2007 schedule, investigators typically advance one zone per injection day and mark the sequence on a simple tracking chart.
Within each zone, individual injection points should be separated by at least 1-2 cm from the previous point used in that zone. Over an 8-week research cycle this generates approximately 40-56 distinct needle entry coordinates across the abdominal surface — a surface large enough to support this without overlap if the outer boundaries are respected.
| Day | Zone | Position | Approximate Coordinates |
|---|---|---|---|
| Day 1 | L1 | Left upper-inner | 2-3 cm left, 2-3 cm above navel |
| Day 2 | L2 | Left upper-outer | 6-8 cm left, 2-3 cm above navel |
| Day 3 | R2 | Right upper-outer | 6-8 cm right, 2-3 cm above navel |
| Day 4 | R1 | Right upper-inner | 2-3 cm right, 2-3 cm above navel |
| Day 5 | R3 | Right lower-inner | 2-3 cm right, 2-3 cm below navel |
| Day 6 | R4 | Right lower-outer | 6-8 cm right, 2-3 cm below navel |
| Day 7 | L4 | Left lower-outer | 6-8 cm left, 2-3 cm below navel |
| Day 8 | L3 | Left lower-inner | 2-3 cm left, 2-3 cm below navel |
| Day 9+ | L1 (new point) | Cycle restarts, 1-2 cm shift within zone | Advance coordinates within zone boundary |
The Falutz 2007 investigational product was administered SC at a 45-degree angle with a 27-30 gauge, 8 mm needle. For leaner subjects — where the SC layer above the fascia is thinner — a shorter 6 mm needle at 90 degrees reduces the risk of inadvertent intramuscular (IM) delivery. IM injection does not destroy tesamorelin but absorbs faster and flattens the pulsatile GH curve the molecule is designed to produce. In a research context, SC consistency is the variable that makes IGF-1 tracking meaningful.
REVIVE LAB UAE stocks tesamorelin in 5 mg and 10 mg lyophilized vials only — no 1 mg or 2 mg vial formats, consistent with research-grade supply standards. The Falutz 2007 trial (412 subjects, NEJM) used 2 mg/day; the Stanley 2014 JAMA NAFLD work used the same 2 mg/day SC dosing and observed a 32% reduction in liver fat versus placebo over 12 months (confirmed by the 2019 Lancet HIV extension). Investigators replicating either protocol should reference those publications directly for dosing rationale — the reconstitution math below is for volume calculation only.
| Vial | BAC Water Added | Concentration | Volume for 1 mg | Volume for 2 mg |
|---|---|---|---|---|
| Tesamorelin 5 mg | 1 mL | 5 mg/mL | 0.20 mL (20 IU) | 0.40 mL (40 IU) |
| Tesamorelin 5 mg | 2 mL | 2.5 mg/mL | 0.40 mL (40 IU) | 0.80 mL (80 IU) |
| Tesamorelin 10 mg | 2 mL | 5 mg/mL | 0.20 mL (20 IU) | 0.40 mL (40 IU) |
| Tesamorelin 10 mg | 4 mL | 2.5 mg/mL | 0.40 mL (40 IU) | 0.80 mL (80 IU) |
Reconstitution technique: insert bacteriostatic water slowly down the inside wall of the vial — never directly onto the lyophilized cake. Swirl gently; do not vortex. The solution should be clear to faintly opalescent. Reconstituted vials should be kept at 2-8°C and used within 14 days. Discard if cloudy or particulate. Investigators running the 8-zone rotation protocol over a 28-day window will typically open a second 10 mg vial around day 10 at 2 mg/day, making the 10 mg format more economical for multi-week protocols.
The four pivotal tesamorelin publications form a coherent dataset that any serious UAE investigator should have on file. The methodological detail on site rotation is understated in the published abstracts but explicit in the supplementary protocols:
The takeaway for investigators: the rotation grid is not an administrative nicety. The IGF-1 biomarker data underpinning both the VAT and NAFLD outcomes depends on consistent SC absorption. A researcher who switches randomly between thigh, deltoid and abdomen will generate IGF-1 curves that are not comparable to the published benchmarks — making the data uninformative regardless of how clean the REVIVE LAB UAE peptide supply is.
Running a coherent rotation protocol requires a reliable supply of research-grade vials. Running out mid-protocol — and restarting after a gap — resets the IGF-1 trajectory and contaminates the longitudinal data. This is the practical argument for sourcing from a UAE-local peptides supplier rather than an overseas courier with 7-14 day lead times.
REVIVE LAB UAE supplies HPLC-verified, lot-COA, cold-chain dispatched tesamorelin across all 7 emirates. Tesamorelin Dubai same day delivery is available for orders placed before the daily cut-off; tesamorelin 24h delivery covers Abu Dhabi, Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain. Cash on delivery Dubai is standard — no prepayment required. Investigators can buy tesamorelin UAE directly from the product page with COA available on request.
| Location | Delivery Window | Cold Chain | Cash on Delivery |
|---|---|---|---|
| Dubai (Marina, JBR, Business Bay, DIFC, JVC, Downtown, Palm, Jumeirah) | Same-day, 4-8 hours | Yes | Yes |
| Abu Dhabi (Corniche, Yas, Saadiyat, Reem) | Next-day, 18-24 hours | Yes | Yes |
| Sharjah | Same-day / next-day, 8-18 hours | Yes | Yes |
| Ajman / RAK / UAQ | Next-day, 18-24 hours | Yes | Yes |
| Fujairah / Al Ain | Next-day, 24 hours | Yes | Yes |
Every REVIVE LAB UAE tesamorelin shipment uses plain, unbranded outer cartons with validated insulated packaging holding 2-8°C through UAE summer courier transit. The cold chain is not a marketing claim — it is a prerequisite for research-grade peptide delivery in a country where ambient summer temperatures regularly exceed 44°C.
REVIVE LAB UAE stocks HPLC-verified tesamorelin 5 mg and 10 mg vials and dispatches same-day in Dubai for orders placed before the daily cut-off. Cash on delivery Dubai is available at checkout — no prepayment required. For Abu Dhabi, Sharjah, Ajman, Ras Al Khaimah, Fujairah and all other emirates, tesamorelin 24h delivery is the standard window. All shipments use cold-chain validated packaging and plain unbranded outer cartons. Visit /buy-tesamorelin-uae/ to order.
REVIVE LAB UAE stocks tesamorelin in 5 mg and 10 mg lyophilized vials only. No 1 mg or 2 mg vial formats are stocked — REVIVE LAB UAE carries research-grade formats that match the Falutz 2007 and Stanley 2014 trial supply specifications. A 10 mg vial reconstituted to 2 mg/mL covers a standard 5-injection research window at 2 mg/day dosing; investigators running multi-week protocols typically order 2-3 vials at a time to avoid supply gaps mid-cycle. Lot-level COA is available on request for every batch.
The protocol used in the Falutz and Stanley trials divides the periumbilical abdomen into 8 zones: 4 on the left (upper-inner, upper-outer, lower-inner, lower-outer) and 4 mirrored on the right, each at least 2 cm from the umbilicus. Investigators rotate clockwise through all 8 zones before revisiting any single zone, producing a minimum 7-day rest per site at once-daily dosing. Within each zone, successive injections are spaced 1-2 cm apart. The 45-degree, 27-30 gauge SC technique used in the NEJM lipodystrophy trial delivers the molecule to the hypodermis without intramuscular contamination — maintaining the pulsatile GH curve that tesamorelin's GHRH-analog mechanism is designed to produce.